vs
BIOCRYST PHARMACEUTICALS INC（BCRX）与REPUBLIC BANCORP INC（RBCAA）财务数据对比。点击上方公司名可切换其他公司
BIOCRYST PHARMACEUTICALS INC的季度营收约是REPUBLIC BANCORP INC的1.7倍（$156.4M vs $94.3M），BIOCRYST PHARMACEUTICALS INC同比增速更快（7.5% vs 5.3%），过去两年BIOCRYST PHARMACEUTICALS INC的营收复合增速更高（19.6% vs -11.5%）
BioCryst Pharmaceuticals是一家总部位于美国北卡罗来纳州达勒姆的制药企业，属于后期发展阶段的生物科技公司，聚焦于治疗罕见重症的口服药物研发。其研发的抗病毒药物帕拉米韦（商品名Rapivab）于2014年12月获得美国FDA批准，此后也陆续在日本、韩国与中国获批上市。
肯塔基州共和银行是美国的一家区域性银行控股企业，提供零售及商业银行全品类服务，涵盖个人存贷款、企业融资、按揭产品及财富管理解决方案，主要服务肯塔基州及周边州的个人消费者和中小企业客户。
BCRX vs RBCAA — 直观对比
营收规模更大
BCRX
是对方的1.7倍
$94.3M
营收增速更快
BCRX
高出2.2%
5.3%
两年增速更快
BCRX
近两年复合增速
-11.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $156.4M | $94.3M |
| 净利润 | — | $22.8M |
| 毛利率 | — | — |
| 营业利润率 | 13.6% | 29.3% |
| 净利率 | — | 24.2% |
| 营收同比 | 7.5% | 5.3% |
| 净利润同比 | — | 20.0% |
| 每股收益（稀释后） | $0.00 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BCRXRBCAA
| Q1 26 | $156.4M | — | ||
| Q4 25 | $406.6M | $94.3M | ||
| Q3 25 | $159.4M | $93.5M | ||
| Q2 25 | $163.4M | $93.8M | ||
| Q1 25 | $145.5M | $135.8M | ||
| Q4 24 | $131.5M | $89.5M | ||
| Q3 24 | $117.1M | $88.1M | ||
| Q2 24 | $109.3M | $86.9M |
净利润BCRXRBCAA
| Q1 26 | — | — | ||
| Q4 25 | $245.8M | $22.8M | ||
| Q3 25 | $12.9M | $29.7M | ||
| Q2 25 | $5.1M | $31.5M | ||
| Q1 25 | $32.0K | $47.3M | ||
| Q4 24 | $-26.8M | $19.0M | ||
| Q3 24 | $-14.0M | $26.5M | ||
| Q2 24 | $-12.7M | $25.2M |
毛利率BCRXRBCAA
| Q1 26 | — | — | ||
| Q4 25 | 97.7% | — | ||
| Q3 25 | 98.6% | — | ||
| Q2 25 | 98.3% | — | ||
| Q1 25 | 96.9% | — | ||
| Q4 24 | 95.4% | — | ||
| Q3 24 | 97.3% | — | ||
| Q2 24 | 98.4% | — |
营业利润率BCRXRBCAA
| Q1 26 | 13.6% | — | ||
| Q4 25 | 64.0% | 29.3% | ||
| Q3 25 | 18.6% | 40.4% | ||
| Q2 25 | 18.2% | 43.0% | ||
| Q1 25 | 14.6% | 44.1% | ||
| Q4 24 | -3.4% | 25.8% | ||
| Q3 24 | 6.6% | 38.4% | ||
| Q2 24 | 8.0% | 37.0% |
净利率BCRXRBCAA
| Q1 26 | — | — | ||
| Q4 25 | 60.5% | 24.2% | ||
| Q3 25 | 8.1% | 31.8% | ||
| Q2 25 | 3.1% | 33.5% | ||
| Q1 25 | 0.0% | 34.8% | ||
| Q4 24 | -20.4% | 21.2% | ||
| Q3 24 | -12.0% | 30.1% | ||
| Q2 24 | -11.6% | 29.0% |
每股收益（稀释后）BCRXRBCAA
| Q1 26 | $0.00 | — | ||
| Q4 25 | $1.13 | — | ||
| Q3 25 | $0.06 | — | ||
| Q2 25 | $0.02 | — | ||
| Q1 25 | $0.00 | — | ||
| Q4 24 | $-0.13 | — | ||
| Q3 24 | $-0.07 | — | ||
| Q2 24 | $-0.06 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $259.0M | $220.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $1.1B |
| 总资产 | $465.1M | $7.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BCRXRBCAA
| Q1 26 | $259.0M | — | ||
| Q4 25 | $274.7M | $220.0M | ||
| Q3 25 | $212.9M | $484.2M | ||
| Q2 25 | $260.0M | $484.8M | ||
| Q1 25 | $295.1M | $793.0M | ||
| Q4 24 | $320.9M | $432.2M | ||
| Q3 24 | $96.8M | $530.9M | ||
| Q2 24 | $78.4M | $400.1M |
股东权益BCRXRBCAA
| Q1 26 | — | — | ||
| Q4 25 | $-119.2M | $1.1B | ||
| Q3 25 | $-387.9M | $1.1B | ||
| Q2 25 | $-421.6M | $1.1B | ||
| Q1 25 | $-451.9M | $1.0B | ||
| Q4 24 | $-475.9M | $992.0M | ||
| Q3 24 | $-468.6M | $979.7M | ||
| Q2 24 | $-475.6M | $955.4M |
总资产BCRXRBCAA
| Q1 26 | $465.1M | — | ||
| Q4 25 | $514.2M | $7.0B | ||
| Q3 25 | $446.4M | $7.0B | ||
| Q2 25 | $457.2M | $7.0B | ||
| Q1 25 | $480.0M | $7.1B | ||
| Q4 24 | $490.4M | $6.8B | ||
| Q3 24 | $491.3M | $6.7B | ||
| Q2 24 | $472.4M | $6.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $168.2M |
| 自由现金流经营现金流 - 资本支出 | — | $161.1M |
| 自由现金流率自由现金流/营收 | — | 170.9% |
| 资本支出强度资本支出/营收 | — | 7.5% |
| 现金转化率经营现金流/净利润 | — | 7.37× |
| 过去12个月自由现金流最近4个季度 | — | $288.6M |
8季度趋势，按日历期对齐
经营现金流BCRXRBCAA
| Q1 26 | — | — | ||
| Q4 25 | $292.0M | $168.2M | ||
| Q3 25 | $41.6M | $33.3M | ||
| Q2 25 | $41.3M | $8.4M | ||
| Q1 25 | $-27.5M | $93.2M | ||
| Q4 24 | $-5.2M | $149.0M | ||
| Q3 24 | $8.2M | $51.3M | ||
| Q2 24 | $-1.4M | $4.0M |
自由现金流BCRXRBCAA
| Q1 26 | — | — | ||
| Q4 25 | $291.2M | $161.1M | ||
| Q3 25 | $40.3M | $30.8M | ||
| Q2 25 | $41.1M | $5.2M | ||
| Q1 25 | $-27.7M | $91.6M | ||
| Q4 24 | $-5.9M | $143.2M | ||
| Q3 24 | $8.2M | $49.8M | ||
| Q2 24 | $-1.5M | $2.7M |
自由现金流率BCRXRBCAA
| Q1 26 | — | — | ||
| Q4 25 | 71.6% | 170.9% | ||
| Q3 25 | 25.3% | 32.9% | ||
| Q2 25 | 25.2% | 5.5% | ||
| Q1 25 | -19.0% | 67.4% | ||
| Q4 24 | -4.5% | 160.0% | ||
| Q3 24 | 7.0% | 56.5% | ||
| Q2 24 | -1.4% | 3.1% |
资本支出强度BCRXRBCAA
| Q1 26 | — | — | ||
| Q4 25 | 0.2% | 7.5% | ||
| Q3 25 | 0.8% | 2.6% | ||
| Q2 25 | 0.1% | 3.5% | ||
| Q1 25 | 0.1% | 1.2% | ||
| Q4 24 | 0.5% | 6.5% | ||
| Q3 24 | 0.1% | 1.7% | ||
| Q2 24 | 0.1% | 1.5% |
现金转化率BCRXRBCAA
| Q1 26 | — | — | ||
| Q4 25 | 1.19× | 7.37× | ||
| Q3 25 | 3.23× | 1.12× | ||
| Q2 25 | 8.12× | 0.27× | ||
| Q1 25 | -859.91× | 1.97× | ||
| Q4 24 | — | 7.84× | ||
| Q3 24 | — | 1.93× | ||
| Q2 24 | — | 0.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BCRX
| ORLADEYO | $148.3M | 95% |
| Other revenues | $5.0M | 3% |
| License revenue | $3.0M | 2% |
RBCAA
暂无分部数据
